01 Mar '23 at 8:20 am #54124
Participant
Reata Pharmaceuticals, Inc. (RETA 86.48, +55.31, +177.4%): Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
- This reply was modified 3 weeks, 2 days ago by
TradersCom.